Edition:
United States

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

45.70CHF
11:30am EST
Change (% chg)

CHF-0.22 (-0.48%)
Prev Close
CHF45.92
Open
CHF46.20
Day's High
CHF46.60
Day's Low
CHF45.22
Volume
20,516
Avg. Vol
69,668
52-wk High
CHF81.45
52-wk Low
CHF44.02

Select another date:

Wed, Nov 14 2018

BRIEF-Basilea Presents Preclinical Data On Anticancer Drug Candidate Bal101553 At Eortc-Nci-Aacr Symposium

* BASILEA PRESENTS PRECLINICAL DATA ON ITS ANTICANCER DRUG CANDIDATE BAL101553 AT EORTC-NCI-AACR SYMPOSIUM Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Pharmaceutica Sees 2018 Oper Loss At CHF 25-35 Mln

* H1 OPERATING LOSS OF CHF 20.4 MILLION COMPARED TO CHF 19.1 MILLION IN H1 2017

BRIEF-Basilea Pharmaceutica: Approval For Antifungal Cresemba (Isavuconazole) In Jordan

* HIKMA PHARMACEUTICALS LLC, GAINED REGULATORY APPROVAL FOR ANTIFUNGAL CRESEMBA (ISAVUCONAZOLE) IN JORDAN Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Starts Clinical Phase 3 Study With Antibiotic Ceftobiprole In Staphylococcus Aureus Bacteremia

* BASILEA STARTS CLINICAL PHASE 3 STUDY WITH ANTIBIOTIC CEFTOBIPROLE IN STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Pharmaceutica Reports Receipt Of Payment Based On First Cresemba Approval In Latin America

* REPORTS RECEIPT OF MILESTONE PAYMENT BASED ON FIRST CRESEMBA® APPROVAL IN LATIN AMERICA

BRIEF-Basilea Pharmaceutica Presents Phase 1 Clinical Data With Anticancer Drug Candidate Bal101553

* REPORTS PRESENTATION OF PHASE 1 CLINICAL DATA WITH ANTICANCER DRUG CANDIDATE BAL101553 AT ASCO MEETING

Select another date: